02/03/2016 - 2:52pm
ZembraceSymTouch marks the first approval Dr. Reddy’s has received from the FDA for a brand-name product in its neurology portfolio. 
02/03/2016 - 2:18pm
The new company will focus on the development and commercialization of novel- and science-based dietary supplements and over-the-counter drugs.
02/03/2016 - 2:03pm
Fitbit Alta delivers all the most important activity stats one can expect from Fitbit right on the wrist, along with new features designed to make health and fitness tracking easier and more motivating. 
02/03/2016 - 1:41pm

Joule’s proprietary patch provides an immediate energy boost the moment it is placed on the skin compared to caffeine through other forms, the company stated. 

02/03/2016 - 1:40pm

The asthma treatment is a once-daily dose of two 1.25-microgram puffs. 

02/03/2016 - 1:30pm

Is urgent care the next evolution of today's rapidly expanding retail clinics? On Wednesday Forbes speculated that the fast-growing urgent care market may be ripe for an entry from CVS Health or Walgreens Boots Alliance. "CVS or Walgreens will attempt to enter the standalone urgent care and primary care spaces in the next 12 to 24 months," suggested Gordon Maner, managing partner Allen Mooney Barnes in a recent report, Forbes noted. "Walmart, Target and other consumer-driven businesses will attempt to increase touch points with customers via immediate and scheduled healthcare services, although they will struggle to find profitability." (Forbes)

02/03/2016 - 1:25pm

Discount fashion retailer H&M is expanding its line of beauty products to better appeal to today's eco-conscious shopper.

02/03/2016 - 1:04pm

Baileys has blended the top two flavors in the coffee creamer category into one flavor that coffee drinkers may love.

02/03/2016 - 1:04pm

Reuters is reporting that in 2016, there will likely be seven blockbuster drugs launched, each of which has potential to see more than $1 billion in annual sales. The ones that are poised to be the biggest are a chronic liver desease drug from Intercept Pharmaceuticals and Gilead’s fixed-dose treatment for H.I.V, which experts forecast could make $2.6 billion and $2 billion, respectively. (Reuters)